Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

doi:10.1097/JTO.0b013e3182286d41

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2011

Nishio Makoto, Yamanaka Takeharu, Matsumoto Kazuko, Kimura Hideharu, Sakai Kazuko, Sakai Asao, Sone Takashi, Horiike Atsushi, Koizumi Fumiaki, Kasahara Kazuo, Ohira Tatsuo, Ikeda Norihiko, Saijo Nagahiro, Arao Tokuzo, Nishio Kazuto

Abstract excerpt

INTRODUCTION: The epidermal growth factor receptor (EGFR) mutation status is a validated biomarker for the stratification of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) treatment in patients with non-small cell lung cancer (NSCLC); however, its use is limited in patients with wild-type EGFR, and new biomarkers are needed. We hypothesized that the serum concentration of heparan sulfate (HS), which activates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Heparitin Sulfate

Share to Neoplasm Staging

Share to Quinazolines

Share to Treatment Failure

Source

Open in PubMed

Identifiers

PMID: 21964526
DOI: 10.1097/JTO.0b013e3182286d41

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.PMID 21964526Read ↗

Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.Semantic proximity Read ↗

Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.Semantic proximity Read ↗

Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.Semantic proximity Read ↗

Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.Semantic proximity Read ↗

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.Semantic proximity Read ↗

Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistanceSemantic proximity Read ↗

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.Semantic proximity Read ↗

Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.